| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6201403 | Ophthalmology | 2015 | 11 Pages |
Abstract
Among Israeli and Palestinian patients, CNGA3 mutations are the leading cause of ACHM. Retinal structural results support the candidacy of CNGA3 ACHM for clinical trials for therapy of cone photoreceptors. Efficacy outcome measures would include chromatic light-adapted psychophysics, with attention to the photoreceptor basis of the response, and quantitation of photoaversion.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Lina PhD, Artur V. PhD, Susanne PhD, Sharon B. MS, CGC, Ada MD, PhD, Dalia PhD, Alexander PhD, Alejandro J. MS, Xunda MD, PhD, Cassondra BS, Boris MD, PhD, Anat PhD, Bernd PhD, Samuel G. MD, PhD, Eyal MD, PhD, Dror PhD,